<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>312-LEVOCARNITINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="LEVOCARNITINE" rxcui="42955">
<ATC code="A16AA01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG2>
<DESCRIPTION>Increase of the effect of the vitamin K antagonist and of the risk of hemorrage</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the levocarnitine and a week after it is stopped. </COMMENT>
</INTERACTION>
</INTERACTIONS>
